Pain didn’t spread as fast
Prostate cancer that has spread—called metastatic cancer—often causes pain as it grows in bones or organs. Hormone therapy, also known as androgen deprivation therapy (ADT), has long been the first step. It works by cutting off the fuel (male hormones) that feed the cancer. But over time, the cancer often comes back stronger.
Doctors have been adding newer drugs to ADT to keep that from happening. Darolutamide is one of them. It blocks the hormone signal even more completely. Think of it like a second lock on a door. ADT turns off the main key. Darolutamide jams the spare keys.
A clearer path to feeling better
In the past, new drugs were judged mainly by how long they kept cancer from growing on scans. That matters. But so does how a man feels every day. Can he walk the dog? Play with his grandkids? Sleep through the night?
The ARANOTE trial looked closely at those questions. It followed 669 men across 15 countries. All had recently diagnosed metastatic prostate cancer. Half took darolutamide with ADT. Half took a placebo with ADT.
They answered regular surveys about pain and overall well-being. The surveys used simple scoring tools. One measured worst pain on a 0 to 10 scale. The other asked about energy, mood, and daily function.
Men on darolutamide felt better longer
Here’s what changed. Men taking darolutamide took about 40% longer to see their pain get worse. That means if pain scores went up by two points or more, or if they needed strong painkillers like opioids for a week or more, it happened later.
They also held on to their quality of life longer. Their overall well-being score dropped 24% slower than men on placebo. That 10-point drop in quality of life? It came months later for those on the drug.
These delays may not sound huge. But in cancer care, months of stable symptoms are meaningful. They mean more time with family, fewer hospital visits, and less need for strong pain drugs.
But there’s a catch.
Side effects were mild but still present
Darolutamide didn’t cause major new side effects. Most men handled it well. The most common serious issues were high blood pressure, low red blood cell counts, and minor liver changes. Rates were similar between groups.
One man in the darolutamide group died from a treatment-related cause. The report lists it as “death not otherwise specified,” meaning the exact reason wasn’t clear. This is rare, but it reminds us that even well-tolerated drugs carry some risk.
This doesn’t mean this treatment is available yet.
Experts say the results add strong support for using darolutamide early in treatment. It’s already approved in some countries for this use. But access varies. Cost, insurance rules, and local guidelines can slow adoption.
Also, the trial didn’t compare darolutamide to other similar drugs like enzalutamide or apalutamide. We don’t yet know which works best or causes the fewest side effects.
Not all men respond the same
The study included men of many backgrounds—White, Asian, Black, and others. Results were consistent across groups. But the number of Black men was small. More research is needed to be sure the benefits are the same for all.
The trial also only included men who were fairly healthy otherwise. Those with severe heart or liver disease weren’t enrolled. So we don’t know how well it works for men with other serious conditions.
More time with fewer symptoms
What happens next? Doctors may start offering darolutamide sooner after diagnosis. Guidelines could change within a year. More data will come as the trial continues.
Researchers will also look at whether the drug helps men live longer. That result isn’t ready yet. Survival takes longer to measure.
For now, the message is clear. Adding darolutamide to standard therapy doesn’t just slow cancer on scans. It helps men feel better, longer. And in advanced cancer, that’s a win.
